Rubicon Research Ltd. (RUBICON) fundamentals
Rubicon Research Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as RUBICON (ISIN INE506V01022). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Rubicon Research Ltd. does
Rubicon Research Ltd is an India-based pharmaceutical formulations company, which is focused on research and development, with a portfolio of specialty products and drug-device combination products targeting regulated markets, and particularly the United States. Its portfolio spans multiple dosage forms, including oral solids, oral liquids, nasal, and topical. Its technologies include RubiReten and RubiSRL. Its services include intellectual property evaluation and product design, formulation research development, analytical research development, technology transfer, dossier compilation and regulatory support, and clinical trials supplies. Its products are spread across many therapeutic areas, such as Analgesics/Pain Management, CVS, CNS, Hypokalemia, Skeletal Muscle Relaxants, NRT, Gastrointestinal, Metabolic, Immunosuppressant, and others. Others include Antipyretic, Hormonal Products, Diuretic, Antimuscarinics, Oral Rehydration Therapy, Over the Counter products, and Respiratory.
Valuation and market data
| Last close | ₹1490.30 |
|---|---|
| Market capitalisation | ₹23,693 crore |
| Enterprise value | ₹23,709 crore |
| P/E (TTM) | 96.02 |
| Price to book | 18.38 |
| Price to sales (TTM) | 7.44 |
| Book value per share | ₹81.07 |
| Dividend yield | 10.07% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Thu Oct 16 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹1,317 crore | ₹253 crore | ₹188 crore | 11.83 |
| Mar 2025 | ₹1,094 crore | ₹223 crore | ₹168 crore | 11.00 |
| Mar 2024 | ₹657 crore | ₹34 crore | ₹24 crore | 1.60 |
| Mar 2023 | ₹419 crore | ₹-11 crore | ₹-17 crore | -1.11 |
| Mar 2022 | ₹417 crore | ₹17 crore | ₹17 crore | 32.91 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 51.3% |
|---|---|
| Foreign institutions (FII) | 9.0% |
| Mutual funds | 13.8% |
| Other domestic institutions | 0.2% |
| Retail and others | 25.8% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.